PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000851336.89795.74 |
| _version_ | 1797287978066771968 |
|---|---|
| author | K. Lorenz T. Strüßmann M. Trepel G. Illerhaus H. Pelz C. Scholz J. Duyster R. Marks |
| author_facet | K. Lorenz T. Strüßmann M. Trepel G. Illerhaus H. Pelz C. Scholz J. Duyster R. Marks |
| author_sort | K. Lorenz |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:42:38Z |
| format | Article |
| id | doaj.art-8ba487860f884ec19fdba3b550acd5af |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:42:38Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-8ba487860f884ec19fdba3b550acd5af2024-03-02T03:29:16ZengWileyHemaSphere2572-92412022-06-0161997199810.1097/01.HS9.0000851336.89795.74202206003-01997PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITYK. Lorenz0T. Strüßmann1M. Trepel2G. Illerhaus3H. Pelz4C. Scholz5J. Duyster6R. Marks71 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg1 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg2 Department of Hematology and Oncology, Universitätsklinikum Augsburg, Augsburg3 Department of Hematology, Oncology, and Palliative Medicine, Klinikum Stuttgart, Stuttgart4 Onkologie Offenburg, Offenburg5 Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany1 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburg1 Department of Hematology and Oncology, Universitätsklinikum Freiburg, Freiburghttp://journals.lww.com/10.1097/01.HS9.0000851336.89795.74 |
| spellingShingle | K. Lorenz T. Strüßmann M. Trepel G. Illerhaus H. Pelz C. Scholz J. Duyster R. Marks PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY HemaSphere |
| title | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_full | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_fullStr | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_full_unstemmed | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_short | PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY |
| title_sort | pb2126 r cpop as first line treatment for dlbcl patients with significant reduced lvef or high risk of anthracycline induced cardiotoxicity |
| url | http://journals.lww.com/10.1097/01.HS9.0000851336.89795.74 |
| work_keys_str_mv | AT klorenz pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT tstrußmann pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT mtrepel pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT gillerhaus pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT hpelz pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT cscholz pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT jduyster pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity AT rmarks pb2126rcpopasfirstlinetreatmentfordlbclpatientswithsignificantreducedlveforhighriskofanthracyclineinducedcardiotoxicity |